WO2008028192A3 - Variable region sequences of il-31 monoclonal antibodies and methods of use - Google Patents

Variable region sequences of il-31 monoclonal antibodies and methods of use Download PDF

Info

Publication number
WO2008028192A3
WO2008028192A3 PCT/US2007/077555 US2007077555W WO2008028192A3 WO 2008028192 A3 WO2008028192 A3 WO 2008028192A3 US 2007077555 W US2007077555 W US 2007077555W WO 2008028192 A3 WO2008028192 A3 WO 2008028192A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
moieties
compositions
monoclonal antibodies
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/077555
Other languages
French (fr)
Other versions
WO2008028192A2 (en
Inventor
Anthony W Siadak
Janine Bilsborough
Shirley Rene
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2009526951A priority Critical patent/JP2010502652A/en
Priority to CNA2007800366660A priority patent/CN101522713A/en
Priority to US12/439,079 priority patent/US8466262B2/en
Priority to MX2009002242A priority patent/MX2009002242A/en
Priority to BRPI0715660A priority patent/BRPI0715660B8/en
Priority to AU2007290145A priority patent/AU2007290145B2/en
Priority to EP07814672A priority patent/EP2061811A2/en
Priority to KR1020097004994A priority patent/KR101501660B1/en
Priority to CA2660175A priority patent/CA2660175C/en
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of WO2008028192A2 publication Critical patent/WO2008028192A2/en
Publication of WO2008028192A3 publication Critical patent/WO2008028192A3/en
Priority to IL196914A priority patent/IL196914A/en
Anticipated expiration legal-status Critical
Priority to US13/895,008 priority patent/US9011858B2/en
Priority to US14/659,644 priority patent/US9624296B2/en
Priority to US15/455,278 priority patent/US9878038B2/en
Priority to US15/842,173 priority patent/US10434173B2/en
Priority to US16/548,584 priority patent/US20190374637A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Novel compositions derived from antigen-binding sites of immunoglobulins having affinity for IL-31 are provided. The compositions exhibit immunological binding properties of antibody molecules capable of binding specifically to a human IL-31. CDR regions derived from same or different immunoglobulin moieties are provided. Also provided are single chain polypeptides wherein VH and VL domains are attached. The sFv molecules can include ancillary polypeptide moieties which can be bioactive, or which provide a site of attachment for other useful moieties. The compositions are useful in specific binding assays, affinity purification schemes, drug or toxin targeting, imaging, and genetic or immunological therapeutics for inflammatory diseases. The invention thus provides novel polypeptides, the DNAs encoding those polypeptides, expression cassettes comprising those DNAs, and methods of inducing the production of the polypeptides. The invention further provides the amino acid sequences of the variable regions of the monoclonal antibodies and use of these monoclonal antibody or antibody fragment in conjunction with an an human IgG4 Fc molecule.
PCT/US2007/077555 2006-09-01 2007-09-04 Variable region sequences of il-31 monoclonal antibodies and methods of use Ceased WO2008028192A2 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
JP2009526951A JP2010502652A (en) 2006-09-01 2007-09-04 Variable region sequence of IL-31 monoclonal antibody and method of use
CNA2007800366660A CN101522713A (en) 2006-09-01 2007-09-04 Variable region sequences of IL-31 monoclonal antibodies and methods of use
US12/439,079 US8466262B2 (en) 2006-09-01 2007-09-04 Variable region sequences of IL-31 monoclonal antibodies and methods of use
MX2009002242A MX2009002242A (en) 2006-09-01 2007-09-04 Variable region sequences of il-31 monoclonal antibodies and methods of use.
BRPI0715660A BRPI0715660B8 (en) 2006-09-01 2007-09-04 isolated antibody that binds to human IL-31; and, use of a monoclonal antibody
AU2007290145A AU2007290145B2 (en) 2006-09-01 2007-09-04 Variable region sequences of IL-31 monoclonal antibodies and methods of use
EP07814672A EP2061811A2 (en) 2006-09-01 2007-09-04 Variable region sequences of il-31 monoclonal antibodies and methods of use
KR1020097004994A KR101501660B1 (en) 2006-09-01 2007-09-04 Variable region sequences of IL-31 monoclonal antibodies and methods of use
CA2660175A CA2660175C (en) 2006-09-01 2007-09-04 Variable region sequences of il-31 monoclonal antibodies and methods of use
IL196914A IL196914A (en) 2006-09-01 2009-02-05 Isolated monoclonal antibodies with specific variable region sequences which specifically bind il-31, polynucleotide and expression vectors encoding said antibodies, methods of peoduction and uses thereof
US13/895,008 US9011858B2 (en) 2006-09-01 2013-05-15 Variable region sequences of IL-31 monoclonal antibodies and methods of use
US14/659,644 US9624296B2 (en) 2006-09-01 2015-03-17 Polynucleotides encoding IL-31 monoclonal antibodies
US15/455,278 US9878038B2 (en) 2006-09-01 2017-03-10 Methods of treating atopic dermatitis with IL-31 monoclonal antibodies
US15/842,173 US10434173B2 (en) 2006-09-01 2017-12-14 Use of IL-31 monoclonal antibodies for treating pruritus
US16/548,584 US20190374637A1 (en) 2006-09-01 2019-08-22 Use of il-31 monoclonal antibodies for treating prurigo nodularis

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US82440306P 2006-09-01 2006-09-01
US60/824,403 2006-09-01
US89079207P 2007-02-20 2007-02-20
US60/890,792 2007-02-20

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/439,079 A-371-Of-International US8466262B2 (en) 2006-09-01 2007-09-04 Variable region sequences of IL-31 monoclonal antibodies and methods of use
US13/895,008 Continuation US9011858B2 (en) 2006-09-01 2013-05-15 Variable region sequences of IL-31 monoclonal antibodies and methods of use

Publications (2)

Publication Number Publication Date
WO2008028192A2 WO2008028192A2 (en) 2008-03-06
WO2008028192A3 true WO2008028192A3 (en) 2008-05-15

Family

ID=38752366

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/077555 Ceased WO2008028192A2 (en) 2006-09-01 2007-09-04 Variable region sequences of il-31 monoclonal antibodies and methods of use

Country Status (19)

Country Link
US (6) US8466262B2 (en)
EP (3) EP2061811A2 (en)
JP (3) JP2010502652A (en)
KR (1) KR101501660B1 (en)
CN (2) CN101522713A (en)
AU (1) AU2007290145B2 (en)
BR (1) BRPI0715660B8 (en)
CA (1) CA2660175C (en)
CY (1) CY1115939T1 (en)
DK (1) DK2594586T3 (en)
ES (2) ES2519375T3 (en)
HK (1) HK1199047A1 (en)
IL (1) IL196914A (en)
MX (1) MX2009002242A (en)
PL (1) PL2594586T3 (en)
PT (1) PT2594586E (en)
RU (1) RU2009111884A (en)
SI (1) SI2594586T1 (en)
WO (1) WO2008028192A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2835543C1 (en) * 2019-08-29 2025-02-26 Эланко Юс Инк. Anti-il31 antibodies for use in veterinary science

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2490276C2 (en) 2002-01-18 2013-08-20 Займоджинетикс, Инк. New ligand of cytokine receptor zcytor17
JP4927762B2 (en) * 2005-02-14 2012-05-09 ザイモジェネティクス， インコーポレイテッド Method for predicting therapeutic response of atopic dermatitis to IL-31 antagonist
EP1858924A1 (en) 2005-02-14 2007-11-28 ZymoGenetics, Inc. Methods of treating skin disorders using an il-31ra antagonist
CN101198624B (en) 2005-05-06 2012-10-10 津莫吉尼蒂克斯公司 IL-31 monoclonal antibodies and methods of use
US20130216542A1 (en) 2005-05-06 2013-08-22 Zymogenetics, Inc. Variable region sequences of il-31 monoclonal antibodies and methods of use
US8101183B2 (en) 2005-05-06 2012-01-24 Zymogentics, Inc. Variable region sequences of IL-31 monoclonal antibodies
EP2001906A2 (en) 2006-01-10 2008-12-17 Zymogenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using il-31ra and osmrb antagonists
EP2061811A2 (en) * 2006-09-01 2009-05-27 ZymoGenetics, Inc. Variable region sequences of il-31 monoclonal antibodies and methods of use
AU2008204823A1 (en) 2007-01-10 2008-07-17 Zymogenetics, Inc Methods of using IL-31 to treat airway hyper-responsiveness and asthma
SI2796466T1 (en) 2007-12-07 2018-01-31 Zymogenetics, Inc. Humanized antibody molecules specific for IL-31
EP2294085A1 (en) * 2008-06-09 2011-03-16 Novartis AG Antibodies against neisserial factor h binding protein
CN102946904A (en) 2010-06-18 2013-02-27 埃克斯生物科技公司 Arthritis treatment
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
CN103965363B (en) * 2013-02-06 2021-01-15 上海白泽生物科技有限公司 Fusion protein efficiently combined with PD-1 and VEGF, coding sequence and application thereof
HUE056580T2 (en) 2013-05-30 2022-02-28 Kiniksa Pharmaceuticals Ltd Oncostatin M receptor antigen binding proteins
JP6085746B2 (en) * 2014-08-11 2017-03-01 学校法人北里研究所 Method for improving detection sensitivity in detection of anti-thrombopoietin antibody, method for detecting immune thrombocytopenia, and kit
JP6302813B2 (en) * 2014-09-30 2018-03-28 日立ジョンソンコントロールズ空調株式会社 Scroll compressor and refrigeration cycle apparatus using the same
FI3284480T3 (en) * 2015-04-14 2025-09-11 Chugai Pharmaceutical Co Ltd Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient
CN115960235A (en) * 2015-08-28 2023-04-14 艾利妥 Anti-SIGLEC-7 antibodies and methods of use thereof
US11073670B2 (en) 2016-08-12 2021-07-27 Corning Optical Communications LLC Device and method for sealing multiport splitters
JP7252627B2 (en) * 2016-12-15 2023-04-05 デューク ユニバーシティ Antibodies and methods for depleting regulatory B10 cells and their use in combination with immune checkpoint inhibitors
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
HRP20220022T1 (en) 2017-06-28 2022-04-01 Corning Research & Development Corporation Compact fiber optic connectors
US12271040B2 (en) 2017-06-28 2025-04-08 Corning Research & Development Corporation Fiber optic extender ports, assemblies and methods of making the same
US11187859B2 (en) 2017-06-28 2021-11-30 Corning Research & Development Corporation Fiber optic connectors and methods of making the same
US11300746B2 (en) 2017-06-28 2022-04-12 Corning Research & Development Corporation Fiber optic port module inserts, assemblies and methods of making the same
US11668890B2 (en) 2017-06-28 2023-06-06 Corning Research & Development Corporation Multiports and other devices having optical connection ports with securing features and methods of making the same
US12571977B2 (en) 2017-06-28 2026-03-10 Corning Research & Development Corporation Multiports and other devices having optical connection ports with securing features and methods of making the same
WO2019086694A1 (en) * 2017-11-06 2019-05-09 Geert Mudde Il31 antigen and vaccine
JP7449234B2 (en) 2018-03-16 2024-03-13 ゾエティス・サービシーズ・エルエルシー Interleukin 31 monoclonal antibody for veterinary use
CA3093709C (en) 2018-03-16 2024-03-26 Zoetis Services Llc Peptide vaccines against interleukin-31
US10641967B1 (en) 2018-11-16 2020-05-05 Corning Research & Development Corporation Multiport assemblies including a modular adapter support array
US10768382B2 (en) 2018-11-29 2020-09-08 Corning Research & Development Corporation Multiport assemblies including access apertures and a release tool
PL3887883T3 (en) 2018-11-29 2024-04-22 Corning Research & Development Corporation Multiport having connection ports with rotating actuators
CN109528663A (en) * 2018-12-20 2019-03-29 江西润泽药业有限公司 With NGR (NO2) be targeting vector anticancer drug freeze dried powder and its preparation method and application
EP4471478A3 (en) 2018-12-28 2025-03-05 Corning Research and Development Corporation Multiport assemblies including mounting features or dust plugs
US20220220196A1 (en) * 2019-04-24 2022-07-14 Janssen Biotech, Inc. Antibody formulation
WO2020242847A1 (en) 2019-05-31 2020-12-03 Corning Research & Development Corporation Multiports and other devices having optical connection ports with sliding actuators and methods of making the same
WO2020243616A1 (en) * 2019-05-31 2020-12-03 Seattle Children's Hospital D/B/A Seattle Children's Research Institute E-cadherin activating antibodies and uses thereof
US11294133B2 (en) 2019-07-31 2022-04-05 Corning Research & Development Corporation Fiber optic networks using multiports and cable assemblies with cable-to-connector orientation
JP7671275B2 (en) * 2019-08-29 2025-05-01 エランコ・ユーエス・インコーポレイテッド Anti-IL31 antibodies for animals
US11487073B2 (en) 2019-09-30 2022-11-01 Corning Research & Development Corporation Cable input devices having an integrated locking feature and assemblies using the cable input devices
EP3805827B1 (en) 2019-10-07 2025-07-30 Corning Research & Development Corporation Fiber optic terminals and fiber optic networks having variable ratio couplers
PL4045957T3 (en) 2019-10-18 2024-04-29 Corning Research & Development Corporation Terminals having optical connection ports with securing features providing stable retention forces
US11650388B2 (en) 2019-11-14 2023-05-16 Corning Research & Development Corporation Fiber optic networks having a self-supporting optical terminal and methods of installing the optical terminal
WO2021100794A1 (en) 2019-11-20 2021-05-27 中外製薬株式会社 Antibody-containing preparation
US11536921B2 (en) 2020-02-11 2022-12-27 Corning Research & Development Corporation Fiber optic terminals having one or more loopback assemblies
EP4158401A1 (en) 2020-05-26 2023-04-05 Corning Research & Development Corporation Fiber optic connectors having one or more securing buttons
EP4172671B1 (en) 2020-06-29 2026-01-21 Corning Research & Development Corporation Terminals having a multi-fiber optical connection port that inhibits damage from single-fiber connectors
CA3189847A1 (en) 2020-09-01 2022-03-10 Naoki Fukazawa Pharmaceutical composition for prevention and/or treatment of dialysis pruritus containing il-31 antagonist as active ingredient
US11604320B2 (en) 2020-09-30 2023-03-14 Corning Research & Development Corporation Connector assemblies for telecommunication enclosures
PL4237889T3 (en) 2020-10-30 2026-01-26 Corning Research & Development Corporation FEMALE FIBER OPTIC CONNECTORS WITH LOCKING ARM WITH ROCKING MECHANISM
EP4252055B1 (en) 2020-11-25 2026-06-03 Corning Research & Development Corporation Multiports and other devices having optical connection ports with rotating actuators pivotly mounted and methods of making the same
US11994722B2 (en) 2020-11-30 2024-05-28 Corning Research & Development Corporation Fiber optic adapter assemblies including an adapter housing and a locking housing
US11927810B2 (en) 2020-11-30 2024-03-12 Corning Research & Development Corporation Fiber optic adapter assemblies including a conversion housing and a release member
US11686913B2 (en) 2020-11-30 2023-06-27 Corning Research & Development Corporation Fiber optic cable assemblies and connector assemblies having a crimp ring and crimp body and methods of fabricating the same
US11880076B2 (en) 2020-11-30 2024-01-23 Corning Research & Development Corporation Fiber optic adapter assemblies including a conversion housing and a release housing
EP4019546A1 (en) * 2020-12-23 2022-06-29 Numab Therapeutics AG Antibody variable domains that bind il-31
EP4267614A1 (en) * 2020-12-23 2023-11-01 Numab Therapeutics AG Antibody variable domains that bind il-31
CN112480250B (en) * 2020-12-23 2022-03-15 上海交通大学 Anti-human osteopontin antibody and application thereof
EP4019547A1 (en) * 2020-12-23 2022-06-29 Numab Therapeutics AG Multispecific antibodies having specificity for il-4r and il-31
US11947167B2 (en) 2021-05-26 2024-04-02 Corning Research & Development Corporation Fiber optic terminals and tools and methods for adjusting a split ratio of a fiber optic terminal
CN117209604B (en) * 2021-12-02 2024-03-22 北京东方百泰生物科技股份有限公司 An anti-TSLP monoclonal antibody, its antigen-binding fragment and its application
CN115505575B (en) * 2022-11-16 2023-03-24 中国科学院天津工业生物技术研究所 Two hybridoma cell lines secreting canine IL-31 monoclonal antibody and their application
CN117589031B (en) * 2024-01-19 2024-03-19 四川铁道职业学院 Pantograph carbon slide plate abrasion detection tool and detection method thereof
WO2025226834A1 (en) 2024-04-23 2025-10-30 Attovia Therapeutics, Inc. Il31-binding polypeptides and uses thereof
WO2026031154A1 (en) * 2024-08-09 2026-02-12 Zai Lab (Shanghai) Co., Ltd. Binding molecules with an interleukin-31 receptor subunit alpha-antigen-binding domain and uses thereof
WO2026055142A1 (en) 2024-09-03 2026-03-12 Attovia Therapeutics, Inc. Il13 and il31 bispecific polypeptides and uses thereof
US20260167709A1 (en) * 2024-09-11 2026-06-18 Novartis Ag Antibodies targeting il-31

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003060090A2 (en) * 2002-01-18 2003-07-24 Zymogenetics, Inc. Novel cytokine zcytor17 ligand
US20060188500A1 (en) * 2005-02-14 2006-08-24 Leung Donald Y Methods of predicting therpeutic response in atopic dermatitis to IL-31 antagonists
WO2006122079A1 (en) * 2005-05-06 2006-11-16 Zymogenetics, Inc. Il-31 monoclonal antibodies and methods of use

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
IL71691A (en) 1984-04-27 1991-04-15 Yeda Res & Dev Production of interferon-ypsilon
WO1987001130A1 (en) 1985-08-15 1987-02-26 Stauffer Chemical Company Tryptophan producing microorganism
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
JP3101690B2 (en) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド Modifications of or for denatured antibodies
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US4994560A (en) 1987-06-24 1991-02-19 The Dow Chemical Company Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
US5489425A (en) 1987-06-24 1996-02-06 The Dow Chemical Company Functionalized polyamine chelants
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US5756065A (en) 1988-06-24 1998-05-26 The Dow Chemical Company Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents
EP0353450B1 (en) 1988-06-24 1995-03-29 The Dow Chemical Company Macrocyclic bifunctional chelants, complexes thereof and their antibody conjugates
CN1033030C (en) 1988-06-24 1996-10-16 唐化学原料公司 Preparation method of macrocyclic bifunctional chelating agent and its complexes and antibody conjugates
US5274119A (en) 1988-07-01 1993-12-28 The Dow Chemical Company Vicinal diols
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5696239A (en) 1988-10-31 1997-12-09 The Dow Chemical Company Conjugates possessing ortho ligating functionality and complexes thereof
US5342604A (en) 1988-10-31 1994-08-30 The Dow Chemical Company Complexes possessing ortho ligating functionality
KR900005995A (en) 1988-10-31 1990-05-07 우메모또 요시마사 Modified Interleukin-2 and Method of Making the Same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
US5808003A (en) 1989-05-26 1998-09-15 Perimmune Holdings, Inc. Polyaminocarboxylate chelators
EP0739904A1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
FR2650598B1 (en) 1989-08-03 1994-06-03 Rhone Poulenc Sante DERIVATIVES OF ALBUMIN WITH THERAPEUTIC FUNCTION
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
GB2276169A (en) 1990-07-05 1994-09-21 Celltech Ltd Antibodies specific for carcinoembryonic antigen
DK0553244T4 (en) 1990-10-05 2005-08-01 Celldex Therapeutics Inc Targeted immunostimulation with bispecific reagents
AU8727291A (en) 1990-10-29 1992-06-11 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
JPH0578243A (en) * 1990-12-11 1993-03-30 Shiseido Co Ltd Antipruritic agent and antipruritic composition
ATE145428T1 (en) 1990-12-14 1996-12-15 Cell Genesys Inc CHIMERIC CHAINS FOR TRANSDUCTION OF RECEPTOR-CONNECTED SIGNALING PATHWAYS
EP0582595A1 (en) 1991-04-26 1994-02-16 Surface Active Limited Novel antibodies, and methods for their use
DE69233482T2 (en) 1991-05-17 2006-01-12 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
ES2136092T3 (en) 1991-09-23 1999-11-16 Medical Res Council PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES.
US5428139A (en) 1991-12-10 1995-06-27 The Dow Chemical Company Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
FR2686899B1 (en) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
EP1306095A3 (en) 1992-03-05 2003-06-25 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
US5505931A (en) 1993-03-04 1996-04-09 The Dow Chemical Company Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
CA2141602A1 (en) 1992-08-26 1994-03-03 Philip Leder Use of the cytokine ip-10 as an anti-tumor agent
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
CZ25697A3 (en) 1994-07-29 1997-09-17 Smithkline Beecham Plc Novel compounds
EP1658772A3 (en) 1995-01-17 2007-01-17 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
EP1325115B1 (en) 2000-06-26 2016-07-27 ZymoGenetics, Inc. Cytokine receptor zcytor17
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
WO2004003140A2 (en) 2002-01-18 2004-01-08 Zymogenetics, Inc. Cytokine receptor zcytor17 multimers
BR0316643A (en) * 2002-11-27 2005-10-11 Gtc Biotherapeutics Inc Stably modified antibodies produced in milk and method of producing same
JP4958555B2 (en) * 2004-09-22 2012-06-20 協和発酵キリン株式会社 Stabilized human IgG4 antibody
ES2579758T3 (en) 2005-01-28 2016-08-16 Zymogenetics, Inc. Homogeneous preparations of IL-31
EP1858924A1 (en) 2005-02-14 2007-11-28 ZymoGenetics, Inc. Methods of treating skin disorders using an il-31ra antagonist
US8101183B2 (en) * 2005-05-06 2012-01-24 Zymogentics, Inc. Variable region sequences of IL-31 monoclonal antibodies
US20130216542A1 (en) * 2005-05-06 2013-08-22 Zymogenetics, Inc. Variable region sequences of il-31 monoclonal antibodies and methods of use
EP2001906A2 (en) 2006-01-10 2008-12-17 Zymogenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using il-31ra and osmrb antagonists
EP2061811A2 (en) * 2006-09-01 2009-05-27 ZymoGenetics, Inc. Variable region sequences of il-31 monoclonal antibodies and methods of use
SI2796466T1 (en) 2007-12-07 2018-01-31 Zymogenetics, Inc. Humanized antibody molecules specific for IL-31

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003060090A2 (en) * 2002-01-18 2003-07-24 Zymogenetics, Inc. Novel cytokine zcytor17 ligand
US20060188500A1 (en) * 2005-02-14 2006-08-24 Leung Donald Y Methods of predicting therpeutic response in atopic dermatitis to IL-31 antagonists
WO2006122079A1 (en) * 2005-05-06 2006-11-16 Zymogenetics, Inc. Il-31 monoclonal antibodies and methods of use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Monoclonal Anti-human IL-31 Antibody", 18 April 2006, R&D SYSTEMS, INC, ISBN: 1-800-343-7475, XP002461764 *
PRESTA ET AL: "Engineering of therapeutic antibodies to minimize immunogenicity and optimize function", ADVANCED DRUG DELIVERY REVIEWS, AMSTERDAM, NL, vol. 58, no. 5-6, 7 August 2006 (2006-08-07), pages 640 - 656, XP005611419, ISSN: 0169-409X *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2835543C1 (en) * 2019-08-29 2025-02-26 Эланко Юс Инк. Anti-il31 antibodies for use in veterinary science

Also Published As

Publication number Publication date
EP2759549A3 (en) 2014-08-27
US20190374637A1 (en) 2019-12-12
US8466262B2 (en) 2013-06-18
WO2008028192A2 (en) 2008-03-06
JP2010502652A (en) 2010-01-28
MX2009002242A (en) 2009-03-13
HK1199047A1 (en) 2015-06-19
US20150183869A1 (en) 2015-07-02
EP2594586A1 (en) 2013-05-22
EP2061811A2 (en) 2009-05-27
CN101522713A (en) 2009-09-02
EP2594586B1 (en) 2014-08-27
US10434173B2 (en) 2019-10-08
US20100008909A1 (en) 2010-01-14
DK2594586T3 (en) 2014-11-17
US20130266562A1 (en) 2013-10-10
KR101501660B1 (en) 2015-03-11
US9011858B2 (en) 2015-04-21
AU2007290145B2 (en) 2012-11-01
RU2009111884A (en) 2010-10-10
BRPI0715660B1 (en) 2018-06-19
CY1115939T1 (en) 2017-01-25
JP2014122220A (en) 2014-07-03
EP2759549A2 (en) 2014-07-30
IL196914A (en) 2014-12-31
CN103044550A (en) 2013-04-17
ES2519375T3 (en) 2014-11-06
BRPI0715660A2 (en) 2013-07-02
US20170182160A1 (en) 2017-06-29
PT2594586E (en) 2014-11-26
SI2594586T1 (en) 2014-11-28
PL2594586T3 (en) 2015-02-27
AU2007290145A1 (en) 2008-03-06
US9878038B2 (en) 2018-01-30
JP6174481B2 (en) 2017-08-02
US20190038743A1 (en) 2019-02-07
IL196914A0 (en) 2011-08-01
CA2660175C (en) 2015-05-12
ES2548714T3 (en) 2015-10-20
US9624296B2 (en) 2017-04-18
BRPI0715660B8 (en) 2021-05-25
CA2660175A1 (en) 2008-03-06
EP2759549B1 (en) 2015-08-19
JP2016106105A (en) 2016-06-16
KR20090113818A (en) 2009-11-02

Similar Documents

Publication Publication Date Title
JP6959390B2 (en) Antibodies and methods of use that target B cell maturation antigens
CY1115939T1 (en) IL-31 Monoclonal Antibodies and Methods of Use
IL316293A (en) Improved serum albumin binding agents
CA2604357A1 (en) P-cadherin antibodies
JP7821159B2 (en) Single variable domains and antigen-binding molecules that bind BCMA
JP2020124203A (en) Blood brain barrier transport molecules and uses thereof
AU2014370883A1 (en) Human anti-IL-33 neutralizing monoclonal antibody
FI3309176T3 (en) Immunoglobulin single variable domain antibodies against ox40l, constructs and their therapeutic use
JP2013506428A5 (en)
IL212056A0 (en) Monoclonal antibodies and methods for their use in the detection of cervical disease
KR102734387B1 (en) Anti-alpha-synuclein antibodies and uses thereof
JP2017509323A5 (en)
JP2023506262A (en) Anti-BCMA CAR Antibodies, Conjugates and Methods of Use
US10633423B2 (en) IL-6-binding polypeptide complex
CN112243381A (en) Anti-BCMA CAR Antibodies, Conjugates and Methods of Use
JP7821161B2 (en) Single variable domains and antigen-binding molecules that bind BCMA
HRP20120975T1 (en) Therapeutic use of anti-cs1 antibodies
US20230242677A1 (en) Multi-specific antibodies
CN117820475B (en) Novel nano antibody aiming at IL-17A, medicine, preparation method and application
US20190225680A1 (en) Tenascin Epitope and Antibodies Thereto
WO2016061632A1 (en) Fn14-binding proteins and uses thereof
CN121895452A (en) Antibodies against activin type 2 receptors and uses thereof
WO2025223473A1 (en) Anti-gdf-15 antibody and use thereof
HK40058700A (en) Antibodies targeting b-cell maturation antigen and methods of use
JP2012179017A (en) Method of preparing protein a-binding protein

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780036666.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07814672

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2660175

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 196914

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2007290145

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2009526951

Country of ref document: JP

Ref document number: MX/A/2009/002242

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007290145

Country of ref document: AU

Date of ref document: 20070904

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020097004994

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1786/CHENP/2009

Country of ref document: IN

Ref document number: 2007814672

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2009111884

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12439079

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0715660

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090226